Ann: Incannex Undertakes A$13 Million Institutional Placement, page-26

The silver lining is the consortium allegedly has expertise in helping healthcare companies transition from R&D to drug commercialisation. How much they will move the needle here, who knows. But it’s good to see that they approached IHL first, must mean they expect good things in future. I think patience will certainly pay here but people are being far too optimistic about the shorter term imo. Let’s hope we have created a lot of value before the next cap raise in 2025 (unless they do another dilutive raise as a discount to the market after emphasising how well funded they are).